[Skip to Content]
[Skip to Content Landing]
January 1975

Mouse Myeloma: A Model for Studies of Cell Kinetics

Author Affiliations

From the Department of Medicine, Ontario Cancer Institute and the University of Toronto, Toronto (Dr. Bergsagel); the Department of Medicine, Section of Hematology, Medical University of South Carolina, Charleston (Dr. Ogawa); and the Department of Family and Community Teaching, University of Toronto, Toronto (Dr. Librach).

Arch Intern Med. 1975;135(1):109-113. doi:10.1001/archinte.1975.00330010111014

The mouse plasma cell tumor Adj PC-5 grows slowly due to a large loss of cells from the growth fraction into nonproliferative, end-stage cells. All tumor cells with the capacity to form a colony appear to be in cell cycle. Marked tumor specificity of several alkylating agents could not be explained by differences in the proliferative state of myeloma and normal marrow cells. Increased sensitivity of myeloma cells to alkylating agents results from intrinsic differences between these and normal marrow cells. The sensitivity of different mouse myelomas to an alkylating agent varies considerably. The factors determining whether a mouse myeloma is sensitive to an alkylating agent are probably related to structure of the agent and intrinsic properties of the cell, rather than to the agent's mechanism of action.